Directed new share issue in Karo Bio (SE) — SEK 202 million

Carnegie acted as lead manager in a directed new share issue of SEK 202 million, allocated to Swedish and international investors. Karo Bio develops drugs based on nuclear receptor mechanisms.May, 2000.